Sulková Sylvie Dusilová, Pokorná Anita, Šafránek Roman, Pavlíková Ladislava, Palička Vladimír
Vnitr Lek. 2021 Winter;67(5):258-263.
Metabolic bone disease in chronic kidney disease and end-stage renal failure represents one of the most severe clinical complication in kidney patients, namely those on maintenance dialysis. Traditionally, bone changes are induced by secondary hyperparathyroidism. The CKD-MBD concept reflects the link between bone and cardiovascular disease in these patients. Studies documented also other bone pathological pathways in renal patients, such as osteoporosis, as in kidney and dialysis patients its risk factors are present as well as in general population. Resulting bone disease in renal disease and failure is far more complex than previously seen. However, the secondary hyperparathyroidism still represents the main pathological pathway.
慢性肾脏病和终末期肾衰竭中的代谢性骨病是肾病患者（即接受维持性透析的患者）最严重的临床并发症之一。传统上，骨骼变化是由继发性甲状旁腺功能亢进引起的。慢性肾脏病-矿物质和骨异常（CKD-MBD）概念反映了这些患者骨骼与心血管疾病之间的联系。研究还记录了肾病患者的其他骨病理途径，如骨质疏松症，因为在肾病和透析患者中，其风险因素与普通人群一样存在。肾病和肾衰竭导致的骨病远比之前所认识的更为复杂。然而，继发性甲状旁腺功能亢进仍然是主要的病理途径。
